Pfizer announced positive topline results from the final overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA in combination with XTANDI for patients with metastatic castration-resistant prostate cancer (mCRPC). The combination demonstrated a statistically significant and clinically meaningful improvement in OS.
The improved survival was observed in both the all-comers patient cohort and in those with homologous recombination repair (HRR) gene-mutated mCRPC, compared to XTANDI alone. This marks TALZENNA plus XTANDI as the first and only PARP inhibitor in combination with an ARPI to significantly improve survival in mCRPC patients, regardless of mutation status.
The safety profile of the combination was generally consistent with the known safety profile of each medicine. Detailed results will be submitted for presentation at an upcoming medical congress and shared with global health authorities to support potential regulatory filings for an expanded label for TALZENNA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.